Semma Therapeutics Obtains $44,000,000 Series A Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=dffdfc24-83c5-427a-8f63-29474e5ee1a3 - Date
3/25/2015 - Company Name
Semma Therapeutics - Mailing Address
Undisclosed Cambridge, MA 02139 USA - Company Description
Semma Therapeutics was founded to develop transformative therapies for patients who currently depend on insulin injections. Recent work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. These cells develop in islet-like clusters grown from stem cells. Initial preclinical work in animal models of diabetes has shown that transplantation of these cells are sufficient to control blood glucose levels. This breakthrough technology has been exclusively licensed to Semma Therapeutics for the development of a cell-based therapy for diabetes. - Website
http://www.semma-tx.com - Transaction Type
Venture Equity - Transaction Amount
$44,000,000 - Transaction Round
Series A - Proceeds Purposes
Proceeds purposes were not disclosed. - M&A Terms
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
